COMPANY

Halia Therapeutics

HQ: Lehi, UT source · haliatx.com ↗ · Mountain

Location: Lehi, UT · source · Oct 14, 2026

Profile checked Oct 10, 2026

Keywords: Myelodysplastic Syndromes Anemia Myelodysplastic Syndrome Anemia in Myelodysplastic Syndromes Alzheimers Disease Type 2 Diabetes Mellitus Obesity HT-6184 HT-4253 Ofirnoflast

7Trials (company is sponsor)

Funding and NIH signals

SEC Form D raise Raised $3.49M (Form D filed Aug 31, 2026). SEC Form D 0001829255-26-000001 (Aug 31, 2026)
Evidence (1 event)
- Aug 31, 2026 · SEC Form D 0001829255-26-000001
  Name of Issuer: Halia Therapeutics, Inc.; CIK: 1829255; Address: Lehi, UT; Submission type: D; Filing date: 2026-08-31; Industry Group: Biotechnology; Date of First Sale: 2026-08-17; Types of Securities Offered: Equity, Option/warrant, Other (Convertible Promissory Notes); Business combination transaction: false; Total Offering Amount: 20000000; Total Amount Sold: 3486474; Federal exemptions: 06b

Job counts as of Oct 18, 2026. All funding and NIH signals

Timeline

2026-11 Trial start Phase 2: A Study to Evaluate Ofirnoflast in Adults With Very Low- to Intermediate-risk Myelodysplastic Syndromes Requiring Red Blood Cell Transfusions source ↗
May 12, 2026 Trial start Phase 2: Study to Evaluate the Effect of HT-4253 for the Prevention of Alzheimer's Disease in APOE4 Carriers source ↗
Jan 6, 2026 Trial start Phase 2: A Ph2 Study to Evaluate the Safety, Efficacy and Tolerability of HT-6184 and Semaglutide in Obese Participants With T2DM source ↗
Sep 17, 2024 Trial start Phase 1: Study to Evaluate HT-4253 in Healthy Subjects source ↗
Feb 12, 2024 Trial start Phase 2: Evaluating Ability of HT-6184 to Reduce Inflammation and Pain After Third Molar Extraction source ↗
Dec 9, 2023 Trial start 2: A Phase 2a Study of HT-6184 in Subjects With IPSS-R Very Low, Low or Intermediate Risk MDS and Anemia source ↗
Jun 15, 2022 Trial start Phase 1: Study to Evaluate HT-6184 in Healthy Subjects source ↗

Upcoming milestones

2028-02 (ESTIMATED) · Phase 2 · Study to Evaluate the Effect of HT-4253 for the Prevention of Alzheimer's Disease in APOE4 Carriers · NCT07399171
2028-10 (ESTIMATED) · Phase 2 · A Study to Evaluate Ofirnoflast in Adults With Very Low- to Intermediate-risk Myelodysplastic Syndromes Requiring Red Blood Cell Transfusions · NCT07738510

Estimated primary completion per ClinicalTrials.gov. Dates move.

Clinical trials (lead sponsor) 7

Record	Title	Phase	Status	Start	Primary completion
NCT07738510	A Study to Evaluate Ofirnoflast in Adults With Very Low- to Intermediate-risk Myelodysplastic Syndromes Requiring Red Blood Cell Transfusions	Phase 2	Not yet recruiting	2026-11	2028-10 (estimated)
NCT07052006	A Phase 2a Study of HT-6184 in Subjects With IPSS-R Very Low, Low or Intermediate Risk MDS and Anemia	2	Active, not recruiting	Dec 9, 2023	Jan 8, 2026 (actual)
NCT07399171	Study to Evaluate the Effect of HT-4253 for the Prevention of Alzheimer's Disease in APOE4 Carriers	Phase 2	Recruiting	May 12, 2026	2028-02 (estimated)
NCT07172867	A Ph2 Study to Evaluate the Safety, Efficacy and Tolerability of HT-6184 and Semaglutide in Obese Participants With T2DM	Phase 2	Withdrawn	Jan 6, 2026	Jan 23, 2026 (actual)
NCT06537817	Study to Evaluate HT-4253 in Healthy Subjects	Phase 1	Completed	Sep 17, 2024	May 12, 2025 (actual)
NCT06241742	Evaluating Ability of HT-6184 to Reduce Inflammation and Pain After Third Molar Extraction	Phase 2	Completed	Feb 12, 2024	Apr 30, 2024 (actual)
NCT05447546	Study to Evaluate HT-6184 in Healthy Subjects	Phase 1	Completed	Jun 15, 2022	Jul 20, 2023 (actual)